- Home
- LEGN vs ADMA Comparison
LEGN vs ADMA Comparison
Compare LEGN & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGN
- ADMA
- Stock Information
- Founded
- LEGN 2014
- ADMA 2004
- Country
- LEGN United States
- ADMA United States
- Employees
- LEGN N/A
- ADMA N/A
- Industry
- LEGN Biotechnology: Pharmaceutical Preparations
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LEGN Health Care
- ADMA Health Care
- Exchange
- LEGN Nasdaq
- ADMA Nasdaq
- Market Cap
- LEGN 5.4B
- ADMA 5.1B
- IPO Year
- LEGN 2020
- ADMA N/A
- Fundamental
- Price
- LEGN $34.00
- ADMA $17.74
- Analyst Decision
- LEGN Strong Buy
- ADMA Strong Buy
- Analyst Count
- LEGN 12
- ADMA 4
- Target Price
- LEGN $77.09
- ADMA $24.25
- AVG Volume (30 Days)
- LEGN 2.0M
- ADMA 2.7M
- Earning Date
- LEGN 08-08-2025
- ADMA 08-07-2025
- Dividend Yield
- LEGN N/A
- ADMA N/A
- EPS Growth
- LEGN N/A
- ADMA N/A
- EPS
- LEGN N/A
- ADMA 0.84
- Revenue
- LEGN $728,303,000.00
- ADMA $459,381,000.00
- Revenue This Year
- LEGN $65.49
- ADMA $23.35
- Revenue Next Year
- LEGN $53.76
- ADMA $27.67
- P/E Ratio
- LEGN N/A
- ADMA $21.27
- Revenue Growth
- LEGN 112.46
- ADMA 62.23
- 52 Week Low
- LEGN $27.34
- ADMA $10.21
- 52 Week High
- LEGN $60.87
- ADMA $25.67
- Technical
- Relative Strength Index (RSI)
- LEGN 53.16
- ADMA 32.83
- Support Level
- LEGN $33.84
- ADMA $20.42
- Resistance Level
- LEGN $35.29
- ADMA $22.37
- Average True Range (ATR)
- LEGN 1.96
- ADMA 0.88
- MACD
- LEGN 0.24
- ADMA -0.28
- Stochastic Oscillator
- LEGN 52.16
- ADMA 1.07
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.